AZD0120: Dual-Targeting CAR-T Therapy Shows Promise in Preclinical Multiple Myeloma Studies

Researchers at AstraZeneca developed AZD0120, a chimeric antigen receptor (CAR)-T cell therapy designed to address limitations in current multiple myeloma treatments, including manufacturing complexity and treatment-related toxicities. The therapy uses a novel dual-targeting approach that recognizes both BCMA and CD19 antigens on cancer cells, combined with an expedited manufacturing process called FasTCAR that aims to shorten production timelines and preserve less-differentiated cell phenotypes. In preclinical testing, AZD0120 demonstrated robust cytotoxicity comparable to existing BCMA-targeted CAR-T therapies in laboratory studies, while the FasTCAR manufacturing process further enhanced performance in animal models, achieving superior tumor control and greater CAR-T cell expansion at lower doses. The therapy maintained minimal unwanted signaling and preserved functional binding to both target antigens. These preclinical findings support advancing AZD0120 into clinical evaluation as a potentially differentiated treatment option that could improve disease control and patient access in multiple myeloma.